Back to Search
Start Over
Limited benefit in patients with MDS receiving venetoclax and azacitidine as a bridge to allogeneic stem cell transplantation
- Source :
- Leukemialymphoma. 63(3)
- Publication Year :
- 2021
-
Abstract
- Myelodysplastic syndromes (MDS) are inherently resistant to chemotherapy leaving allogeneic stem cell transplantation (HCT) as the only curative treatment option. To date it remains unclear how to ...
- Subjects :
- Oncology
Cancer Research
medicine.medical_specialty
medicine.medical_treatment
Azacitidine
Bridge (interpersonal)
chemistry.chemical_compound
hemic and lymphatic diseases
Internal medicine
Medicine
Humans
In patient
Chemotherapy
Sulfonamides
business.industry
Venetoclax
Myelodysplastic syndromes
Hematopoietic Stem Cell Transplantation
Hematology
medicine.disease
Bridged Bicyclo Compounds, Heterocyclic
Transplantation
Leukemia, Myeloid, Acute
surgical procedures, operative
chemistry
Stem cell
business
medicine.drug
Subjects
Details
- ISSN :
- 10292403
- Volume :
- 63
- Issue :
- 3
- Database :
- OpenAIRE
- Journal :
- Leukemialymphoma
- Accession number :
- edsair.doi.dedup.....1d3c8ac39d264228930d3056b25c0dac